Life-threatening hypothyroidism during thyroid hormone withdrawal for routine thyroid cancer surveillance

Endocrinologist

Volumn 17, Issue 2, 2007, Pages 116-118

  Goldberg, Philip ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hypothyroidism; Radioactive iodine; Recombinant human thyrotropin; Thyroid cancer; Thyroid hormone withdrawal

Indexed keywords

IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN; THYROID HORMONE; THYROTROPIN;

ADULT; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CASE REPORT; ENDOCRINE FUNCTION TEST; FEMALE; HUMAN; HYPOTHYROIDISM; IODINE 131 UPTAKE TEST; REVIEW; SENSITIVITY ANALYSIS; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID CARCINOMA; THYROID FUNCTION TEST; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL;

EID: 34247124782     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ten.0000261441.38890.73     Document Type: Review

References (14)

1. Thyroid Carcinoma Task Force. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. Endocr Pract. 2001;7:202-220.
2. Dow KH, Ferrell BR, Ancello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid. 1997;7:613-619.
3. Luster M, Felbinger R, Dietlein M, et al. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirtypatient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid. 2005;15:1147-1155.
4. Tagay S, Herpertz S, Langkafel M, et al. Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. Eur J Endocrinol. 2005;153:755-763.
5. Schroeder PR, Haugen BR, Pacini F, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2006;91:878-884.
6. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877-3885.
7. Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med. 1997;337:888-896.
8. Nicoloff JT, Lopresti JS. Myxedema coma: a form of decompensated hypothyroidism. Endocrinol Metab Clin North Am. 1993;22:279-289.
9. Goldberg PA, Inzucchi SE. Critical issues in endocrinology. Clin Chest Med. 2003;24:583-606.
10. Regalbuto C, Algona C, Maoirana R, et al. Acute changes in clinical parameters and thyroid function peripheral markers following L-T4 withdrawal in patients totally thyroidectomized for thyroid cancer. J Endocrinol Invest. 2006;29:32-40.
11. Grigsby PW, Siegel BA, Bekker S, et al. Preparation of patients with thyroid cancer for 131-I scintigraphy or therapy by 1-3 weeks of thyroxine discontinuation. J Nucl Med. 2004;45:567-570.
12. Guimares V, DeGroot LJ. Moderate hypothyroidism in preparation for whole body 131-I scintiscans and thyroglobulin testing. Thyroid. 1996;6:69-73.
13. Pancini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926-932.
14. Kohlfuerst S, Igerc I, Lind P. Recombinant human thyrotropin is helpful in the follow-up and 131-I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine. Thyroid. 2005;15:371-376.